[go: up one dir, main page]

MX2023011977A - Derivados de (2-((4-((s)-2-(4-cloro-2-fluorofenil)-2-metilbenzo[d] [1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil) -1h-imidazol como activadores del receptor de glp1 para el tratamiento de la obesidad. - Google Patents

Derivados de (2-((4-((s)-2-(4-cloro-2-fluorofenil)-2-metilbenzo[d] [1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil) -1h-imidazol como activadores del receptor de glp1 para el tratamiento de la obesidad.

Info

Publication number
MX2023011977A
MX2023011977A MX2023011977A MX2023011977A MX2023011977A MX 2023011977 A MX2023011977 A MX 2023011977A MX 2023011977 A MX2023011977 A MX 2023011977A MX 2023011977 A MX2023011977 A MX 2023011977A MX 2023011977 A MX2023011977 A MX 2023011977A
Authority
MX
Mexico
Prior art keywords
methyl
methylbenzo
oxetan
piperidin
activators
Prior art date
Application number
MX2023011977A
Other languages
English (en)
Inventor
Troy Smith
Ping Zhang
Daniel Smith
Lihua Yang
Ming Qian
Xilin Zhou
Martin Allan
Lara Czabaniuk
Chung - Yeh Wu
Chun Zhang
Thomas Caya
Matthew Carson
Liansheng Su
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from PCT/IB2022/053367 external-priority patent/WO2022219495A1/en
Publication of MX2023011977A publication Critical patent/MX2023011977A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I) como activadores del receptor del péptido 1 similar al glucagón (GLP1) para el tratamiento de la obesidad, diabetes mellitus tipo 2, resistencia a la insulina, hiperinsulinemia, intolerancia a la glucosa, hiperglucemia, una o más complicaciones diabéticas, nefropatía diabética, dislipidemia, enfermedad del hígado graso no alcohólico (NAFLD), esteatohepatitis no alcohólica (NASH), hipertensión, aterosclerosis, enfermedad arterial periférica, accidente cerebrovascular, miocardiopatía, fibrilación auricular, insuficiencia cardíaca, enfermedad coronaria y neuropatía. Los compuestos preferidos son, por ejemplo, derivados de 2-((4-((S)-2-(4-cloro-2-fluorofenil)-2-metilbenzo[d][1,3]dioxol-4 -il)piperidin-1-il)metil)-1-(((S)-oxetan-2-il)metil)-1H-imidazol y compuestos similares, tales como, por ejemplo, C-1, C-2, C-3, C-4 y otros compuestos.
MX2023011977A 2021-04-12 2022-04-11 Derivados de (2-((4-((s)-2-(4-cloro-2-fluorofenil)-2-metilbenzo[d] [1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil) -1h-imidazol como activadores del receptor de glp1 para el tratamiento de la obesidad. MX2023011977A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163173592P 2021-04-12 2021-04-12
US202263308843P 2022-02-10 2022-02-10
US202263323401P 2022-03-24 2022-03-24
PCT/IB2022/053367 WO2022219495A1 (en) 2021-04-12 2022-04-11 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity

Publications (1)

Publication Number Publication Date
MX2023011977A true MX2023011977A (es) 2023-10-23

Family

ID=88309140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011977A MX2023011977A (es) 2021-04-12 2022-04-11 Derivados de (2-((4-((s)-2-(4-cloro-2-fluorofenil)-2-metilbenzo[d] [1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil) -1h-imidazol como activadores del receptor de glp1 para el tratamiento de la obesidad.

Country Status (9)

Country Link
US (1) US20240182456A1 (es)
EP (1) EP4323354B1 (es)
JP (1) JP2024514826A (es)
KR (1) KR20230170034A (es)
AU (1) AU2022259044A1 (es)
BR (1) BR112023021108A2 (es)
CA (1) CA3215916A1 (es)
IL (1) IL307590A (es)
MX (1) MX2023011977A (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3045644C (en) * 2018-06-13 2024-01-16 Pfizer Inc. Glp-1 receptor agonists and uses thereof
EA202192684A1 (ru) * 2019-04-12 2021-12-28 Цилу Регор Терапьютикс Инк. Агонисты glp-1r и их применения
EP3972596B1 (en) * 2019-05-20 2025-07-16 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
PE20231181A1 (es) * 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos

Also Published As

Publication number Publication date
BR112023021108A2 (pt) 2023-12-12
EP4323354B1 (en) 2025-12-17
KR20230170034A (ko) 2023-12-18
US20240182456A1 (en) 2024-06-06
JP2024514826A (ja) 2024-04-03
IL307590A (en) 2023-12-01
CA3215916A1 (en) 2022-10-20
EP4323354A1 (en) 2024-02-21
AU2022259044A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
CL2023003038A1 (es) Derivados de benzo[d][1,3]dioxol como activadores del receptor glp1 para tratamiento de obesidad
TW206216B (es)
MX2023006186A (es) Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo.
EP2406253B1 (en) Benzofuranyl derivatives used as glucokinase inhibitors
US8450500B2 (en) Pyrrole compounds that modulate HSP90 activity
JP2015187141A5 (es)
CA2448741A1 (en) Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
HRP20120029T1 (hr) Derivati (4(4-[6-trifluorometil-piridin-3-ilamino)-n-sadržavajući-heteroaril]-fenil)-cikloheksil)-octene kiseline i njihove farmaceutske uporabe
Yanagisawa et al. Novel oximes having 5-benzyl-2, 4-thiazolidinedione as antihyperglycemic agents: synthesis and structure–activity relationship
CN1599724A (zh) 咪唑－4－羧酰胺衍生物及其制备和用于治疗肥胖症的方法
CA2438595A1 (en) Glucopyranosyloxypyrazole derivatives and medicinal use thereof
RU2006140795A (ru) Ингибиторы дпп-iv
US20150126499A1 (en) Triazole Compounds that Modulate HSP90 Activity
CA2437240A1 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
JP2013507366A5 (es)
MX2023011977A (es) Derivados de (2-((4-((s)-2-(4-cloro-2-fluorofenil)-2-metilbenzo[d] [1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil) -1h-imidazol como activadores del receptor de glp1 para el tratamiento de la obesidad.
CN1738617A (zh) 用于预防或治疗心血管、心肺、肺部或肾脏疾病的特来沙坦和阿托伐他汀的药物组合物
KR101676889B1 (ko) 페닐이미다졸 화합물
CA1276936C (en) Cardiotonic thiazolones
KR20160049434A (ko) Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
CN1307166C (zh) HPPAR－α受体的噁唑/噻唑衍生物活化剂
JP2013500961A (ja) グルコキナーゼ（ｇｋ）アクチベーターとしての置換ベンズアミド誘導体
Lohray et al. Novel pyrrole-containing hypoglycemic and hypotriglyceridemic compounds
JPWO2023152698A5 (es)
WO2017204319A1 (ja) グルコシルセラミド合成酵素阻害剤